| |
The good news of yesterday's announcement was too quickly overshadowed.
For those who are inclined to visit a medical library, the company's press release was about Volume 21, Supplement 1 of the journal Neurological Research.
The focus of the entire issue (11 papers and an editorial overview) is epidural fibrosis, its clinical significance and the invaluable role of Adcon-L in controlling it.
As a physician, I enjoyed all of the papers and found them instructive.
As an investor in Gliatech, I was overjoyed to see further documentation supporting prophylactic use of Adcon-L.
The editor, Jacques Brotchi, M.D., Ph.D., in the introductory overview states “Our medical experience with Adcon-L has been considerable both in primary surgical cases, and in cases of re-operation. Today, Adcon-L is routinely used in our practice.”
I can foresee a time, in the not too distant future, where a physician will have to explain why he (or she) did not use Adcon-L.
“Standard of Care” here we come.
Note: I also posted this on the Yahoo GLIA board as well. Actually, I posted it last evening and Yahoo lost it (as well as about 10 other posts last night). |
|
